For the quarter ending 2025-09-30, GANX has $10,971,680 in assets. $5,062,250 in debts. $8,807,353 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 8,807,353 | 6,694,136 | ||
| Tax credits | 271,515 | 317,844 | ||
| Prepaid expenses and other current assets | 1,438,400 | 2,294,723 | ||
| Total current assets | 10,517,268 | 9,306,703 | ||
| Property and equipment, net | 85,572 | 96,190 | ||
| Internal-use software, net | 114,607 | 127,857 | ||
| Operating lease right-of-use assets | 184,422 | 233,200 | ||
| Restricted cash | 36,117 | 36,278 | ||
| Long-term deposits and other noncurrent assets | 33,694 | 33,752 | ||
| Total noncurrent assets | 454,412 | 527,277 | ||
| Total assets | 10,971,680 | 9,833,980 | ||
| Accounts payable | 1,577,151 | 2,713,013 | ||
| Operating lease liability - current | 115,910 | 136,320 | ||
| Other current liabilities | 2,340,703 | 2,198,918 | ||
| Deferred grant income - current | 11,293 | 22,685 | ||
| Loans - current | 125,545 | 126,108 | ||
| Total current liabilities | 4,170,602 | 5,197,044 | ||
| Defined benefit pension plan | 527,825 | 522,676 | ||
| Operating lease liability - noncurrent | 65,026 | 92,851 | ||
| Loans - noncurrent | 298,797 | 325,359 | ||
| Total noncurrent liabilities | 891,648 | 940,886 | ||
| Total liabilities | 5,062,250 | 6,137,930 | ||
| Common stock, 0.0001 par value 100,000,000 shares authorized 35,976,390 and 27,132,588 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 3,599 | 3,078 | ||
| Additional paid-in capital | 102,161,036 | 94,642,942 | ||
| Accumulated other comprehensive income (loss) | 563,221 | 584,083 | ||
| Accumulated deficit | -81,194,908 | -81,194,908 | ||
| Loss of the period | -15,623,518 | -10,339,145 | ||
| Total stockholders' equity | 5,909,430 | 3,696,050 | ||
| Total liabilities and stockholders' equity | 10,971,680 | 9,833,980 | ||
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)